Extraordinary shareholders’ meeting held on August 28, 2019 elects three new board members in Mentice AB

The extraordinary shareholders’ meeting held in Mentice AB on August 28, 2019, elected three additional board members.

The extraordinary shareholders’ meeting held on August 28, 2019 in Mentice AB, elected three additional board members proposed by the nomination committee. The extraordinary shareholders’ meeting thereby extended the number of board members in Mentice AB from four to seven members.

The three new board members of Mentice AB consist of Denis Gestin, Gösta Johannesson and David Ballard.

Denis Gestin, born in 1964, B.Sc in Business Administration and Economics, chairman of the board in Holistick Medical, France and Endo Tools Therapeutics and board member of CathVision. Denis Gestin is independent in relation to the company, its management and major shareholders.

Gösta Johannesson, born in 1959, B.Sc in Business Administration and Economics, senior adviser Bure Equity, chairman of the board XVIVO Perfusion, Idevall & Partners fonder, deputy chairman of Interflora and Axiell Group, board member of Yubico, Scandinova and others. Gösta Johannesson is independent in relation to the company, its management but not in relation to one major shareholder.

David Ballard, born in 1956, B.Sc. in Economics, Medical Doctor degree, M. Sc. In Public Health and PhD in Epidemiology, Executive Vice President and Chief Clinical Officer in Mentice and member of the advisory committee for Mentice Inc and Robbins Institute for Health Policy and Leadership, Baylor University. David Ballard is independent in relation to the major shareholders but not in relation to the company and its management. From being elected as a member of the board, David Ballard will be operating purely as a consultant for Mentice and will consequently immediately leave his line management positions and his seat in the executive management team.

For more information, please contact:

Göran Malmberg, CEO, Mentice

E-post: goran.malmberg@mentice.com

US Mobile: +1 (312) 860 5610

Sweden Mobile: +46 (0) 703 09 22 22

Marketplace| Nasdaq First North Premier, Stockholm | Ticker symbol MNTC

Certified Adviser| FNCA Sweden AB, phone +46 8 528 00 399

Mentice is the world leader in software and hardware simulation solutions for endovascular therapies. Our solutions help healthcare professionals acquire, retain, and enhance their procedural skills driving improved productivity and outcomes. Mentice solutions are scientifically validated and have been specifically developed for healthcare providers and the medical device industry. Neurovascular, cardiovascular and peripheral interventions are just some of the clinical areas covered by our solutions. Learn more about the features and benefits of Mentice solutions at: www.mentice.com

About Us

Mentice is the world leader in software and hardware simulation solutions for endovascular therapies. Our solutions help healthcare professionals acquire, retain, and enhance their procedural skills driving improved productivity and outcomes. Mentice solutions are scientifically validated and have been specifically developed for healthcare providers and the medical device industry. Neurovascular, cardiovascular and peripheral interventions are just some of the clinical areas covered by our solutions. Learn more about the features and benefits of Mentice solutions at: www.mentice.com